This article is more than 5 years old. Information may no longer be current.

FDA accepts NDA for Vesneo

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has accepted Bausch + Lomb and Nicox’s new drug application for Vesneo for review, according to a press release from Valeant Pharmaceuticals.

“The acceptance for review of the Vesneo NDA by the FDA marks an important milestone in our effort to bring a new treatment to patients with open angle glaucoma and ocular hypertension,” J. Michael Pearson, CEO and chairman of Valeant, said in the release.

Vesneo (latanoprostene bunod ophthalmic solution 0.024%) is a once-daily IOP-lowering single-agent eye drop for patients with open-angle glaucoma or ocular hypertension.

The FDA has set an action date for July 21, 2016, to complete its review in accordance with the Prescription Drug User Fee Act.